By any measure, 2016 was a great year – a watershed, in fact – for the tech- and pharma-heavy cannabis niche.
For instance, ever since Sept. 2, when I sent my Nova-X Report subscribers the 30 pot stock recommendations in my "weed investors' bible," "The Roadmap to Marijuana Millions," we've seen incredible gains all across the market sector.
And what had been a phenomenal year got even better with a massive victory: On Nov. 8, voters in five states (five juicy untapped markets) voted to legalize medical and recreational marijuana. That boosted the cannabis niche's growth prospects immensely. Remember, this is an investing arena that was already expected to grow by more than 31% a year until at least the early 2020s.
But… the buoyant marijuana markets took notice when President-elect Donald Trump tapped U.S. Sen. Jeff Sessions (R-AL) to be the next U.S. attorney general. The nation's would-be top cop is known for his, shall we say, "retrograde" views on marijuana – legal and otherwise.
That news cast a great deal of uncertainty on investments with an otherwise vertical trajectory.
So, naturally, pot stock investors – and those considering it – are wondering what the future might hold for this high-growth, immensely profitable investing niche.
"A Problem of Resources"
Sen. Sessions is, in fact, an outspoken critic of marijuana.
In an April U.S. Senate meeting, for instance, Sessions said, "We need grown-ups in charge in Washington to say marijuana is not the kind of thing that ought to be legalized."
He also said in the same meeting that "good people don't smoke marijuana."
Still, it's quite a stretch to think that, even in his new position of power, Sessions will be able to effect the kind of massive public policy overhaul it would take to revoke legalization.
Currently, marijuana is illegal under federal law. But because of a congressional rule from 2014, the U.S. Department of Justice is not allowed to use funds to interfere with the implementation of state cannabis laws. Also, a recent Aug. 16 court ruling states the DoJ can no longer prosecute medical marijuana businesses where the defendants are following state laws.
Fundamentally, this means one certain thing: Marijuana legalization is determined by state voters right now.
And it's highly likely to stay that way.
I'm confident of that assertion because of what Donald Trump himself has been telegraphing so far. From a policy perspective, the president-elect is on the record saying marijuana policy is something best left to the states.
Plus, during his confirmation hearing earlier this week, Sessions played down his anti-marijuana stance. While he said he wouldn't "commit to never enforcing federal law" he added that enforcing anti-marijuana laws is "absolutely… a problem of resources for the federal government."
What's more, the president has no power to nullify state laws, and only Congress has the power to pass federal laws. As it stands, Congress' attitude toward marijuana is l…
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.